Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

Next Previous
X
Search
Trial Profile

A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms ENTERPRET
  • Sponsors Takeda

    • Most Recent Events

    • 26 Oct 2022 Results of post hoc pooled analysis (n=1183) assessing the efficacy of vedolizumab at week 6 patients with moderate to severe ulcerative colitis from four phase 3 and 4 clinical trials (ENTERPRET, GEMINI 1, VARSITY, and VISIBLE 1), presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
    • 30 Oct 2020 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 15 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top